Cases & Deals

  • Home
  • Practices
  • Fonds InnoBio acts as selling shareholder in reverse merger of Millendo Therapeutics with OvaScience

Share

Fonds InnoBio acts as selling shareholder in reverse merger of Millendo Therapeutics with OvaScience

December 2018

Client(s) BPI France (Banque Publique d'Investissement)

Jones Day advised Fonds InnoBio, managed by Bpifrance, in connection with the reverse merger of Millendo Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, with OvaScience, Inc. in an all-stock transaction, and concurrent equity financing.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.